Trials / Unknown
UnknownNCT03655483
Study of GLS-010 Injection in the Treatment of Classical Hodgkin's Lymphoma
A Single Arm，Multicenter， Phase II Clinical Study to Evaluate the Efficacy and Safety of GLS-010 Injection in the Treatment of Recurrent or Refractory Classical Hodgkin's Lymphoma
- Status
- Unknown
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 85 (estimated)
- Sponsor
- Guangzhou Gloria Biosciences Co., Ltd. · Industry
- Sex
- All
- Age
- 18 Years – 70 Years
- Healthy volunteers
- Not accepted
Summary
Patients with refractory cHL. Patients will be treated with GLS-010
Detailed description
Open, uncontrolled, multi-center, phase II study.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | GLS-010 | Full-human anti-pd-1 monoclonal antibodies |
Timeline
- Start date
- 2018-08-24
- Primary completion
- 2021-04-11
- Completion
- 2022-04-11
- First posted
- 2018-08-31
- Last updated
- 2020-06-11
Locations
5 sites across 1 country: China
Source: ClinicalTrials.gov record NCT03655483. Inclusion in this directory is not an endorsement.